Empowered Funds LLC Raises Position in IQVIA Holdings Inc. (NYSE:IQV)

Empowered Funds LLC lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 40.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,813 shares of the medical research company's stock after acquiring an additional 1,376 shares during the period. Empowered Funds LLC's holdings in IQVIA were worth $946,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Generate Investment Management Ltd acquired a new stake in IQVIA in the fourth quarter worth $8,262,000. Graphene Investments SAS raised its stake in IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock worth $2,948,000 after buying an additional 2,700 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in IQVIA by 2.6% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,049,912 shares of the medical research company's stock worth $206,318,000 after acquiring an additional 26,648 shares in the last quarter. Silver Oak Securities Incorporated grew its stake in IQVIA by 18.0% in the fourth quarter. Silver Oak Securities Incorporated now owns 2,380 shares of the medical research company's stock valued at $470,000 after acquiring an additional 363 shares during the period. Finally, Bleakley Financial Group LLC increased its holdings in shares of IQVIA by 40.7% in the fourth quarter. Bleakley Financial Group LLC now owns 7,881 shares of the medical research company's stock worth $1,549,000 after acquiring an additional 2,281 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

Insider Activity at IQVIA

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the company's stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average cost of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now directly owns 1,275 shares of the company's stock, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IQV. Stifel Nicolaus decreased their price objective on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Leerink Partners reiterated an "outperform" rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Bank of America lowered their price target on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research note on Friday, December 13th. Robert W. Baird decreased their price target on IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, January 21st. Finally, The Goldman Sachs Group decreased their target price on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IQVIA presently has a consensus rating of "Moderate Buy" and a consensus target price of $251.22.

IQVIA Trading Down 0.3 %

IQV traded down $0.52 during trading on Friday, reaching $193.49. 158,690 shares of the company's stock were exchanged, compared to its average volume of 1,364,575. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The stock has a market capitalization of $34.07 billion, a PE ratio of 25.80, a price-to-earnings-growth ratio of 2.01 and a beta of 1.48. The firm has a fifty day moving average price of $199.73 and a two-hundred day moving average price of $216.79.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.86 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.